Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 2
2006 2
2007 2
2008 4
2009 3
2010 8
2011 4
2012 2
2013 1
2014 7
2015 7
2016 12
2017 6
2018 9
2019 5
2020 18
2021 14
2022 15
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Results by year

Filters applied: . Clear all
Page 1
Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV.
Ramos-Ruperto L, Arcos-Rueda MDM, de Miguel-Buckley R, Busca-Arenzana C, Mican R, Montejano R, Delgado-Hierro A, Montes ML, Valencia ME, Serrano L, Arribas JR, González J, Bernardino JI, Martín-Carbonero L. Ramos-Ruperto L, et al. Among authors: arribas jr. HIV Med. 2024 Feb 20. doi: 10.1111/hiv.13617. Online ahead of print. HIV Med. 2024. PMID: 38379338
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT 022 Study Group. González-Cordón A, et al. J Antimicrob Chemother. 2023 Sep 5;78(9):2361-2365. doi: 10.1093/jac/dkad247. J Antimicrob Chemother. 2023. PMID: 37539492
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice.
Suárez-García I, Alejos B, Hernando V, Viñuela L, Vera García M, Rial-Crestelo D, Pérez Elías MJ, Albendín Iglesias H, Peraire J, Tiraboschi J, Díaz A, Moreno S, Jarrín I; Cohort of the Spanish HIV/AIDS Research Network (CoRIS). Suárez-García I, et al. J Antimicrob Chemother. 2023 Jun 1;78(6):1423-1432. doi: 10.1093/jac/dkad102. J Antimicrob Chemother. 2023. PMID: 37099559 Free PMC article.
Epidemiological characteristic and prognosis changes in chronic hepatitis B in people living with HIV.
Vásquez Manau J, Marcelo Calvo C, De Gea Grela A, Ramos Ruperto L, Serrano L, Busca Arenzana C, Micán R, de Miguel Buckley R, Montejano Sanchez R, Bernardino I, Valencia ME, Moreno V, Montes ML, Arribas JR, González J, Martín-Carbonero L. Vásquez Manau J, et al. Among authors: arribas jr. Enferm Infecc Microbiol Clin (Engl Ed). 2024 Mar;42(3):130-134. doi: 10.1016/j.eimce.2023.03.002. Epub 2023 Mar 30. Enferm Infecc Microbiol Clin (Engl Ed). 2024. PMID: 37003903
Corrigendum to "Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)".
De Miguel R, Rial-Crestelo D, Dominguez-Dominguez L, Montejano R, Esteban-Cantos A, Aranguren-Rivas P, Stella-Ascariz N, Bisbal O, Bermejo-Plaza L, Garcia-Alvarez M, Alejos B, Hernando A, Santacreu-Guerrero M, Cadiñanos J, Mayoral M, Castro JM, Moreno V, Martin-Carbonero L, Delgado R, Rubio R, Pulido F, Arribas JR; ART-PRO, PI16/00837-PI16/00678 study group. De Miguel R, et al. Among authors: arribas jr. EBioMedicine. 2023 Mar;89:104486. doi: 10.1016/j.ebiom.2023.104486. Epub 2023 Feb 18. EBioMedicine. 2023. PMID: 36806001 Free PMC article. No abstract available.
No changes in hemostasis after COVID-19-heterologous vaccination schedule: A subanalysis of the phase 2 CombiVacS study.
Butta NV, Arias-Salgado EG, Monzón Manzano E, Acuña P, Álvarez Román MT, Buño-Soto A, Ramos Ramos JC, Belda-Iniesta C, Frías J, Carcas AJ, de Soto LM, de Miguel Buckley R, Lora D, García-Morales MT, Borobia AM, Arribas JR, Jiménez Yuste V; CombiVacS Study Group. Butta NV, et al. Among authors: arribas jr. Res Pract Thromb Haemost. 2023 Jan;7(1):100049. doi: 10.1016/j.rpth.2023.100049. Epub 2023 Jan 14. Res Pract Thromb Haemost. 2023. PMID: 36685004 Free PMC article.
Treatment and prevention of monkeypox.
de la Calle-Prieto F, Estébanez Muñoz M, Ramírez G, Díaz-Menéndez M, Velasco M, Azkune Galparsoro H, Salavert Lletí M, Mata Forte T, Blanco JL, Mora-Rillo M, Arsuaga M, de Miguel Buckley R, Arribas JR, Membrillo FJ; Working Group of the UAAN – Grupo de Estudio de Patología Importada (GEPI) and the Working Group of the Monkeypox at the SEIMC. de la Calle-Prieto F, et al. Among authors: arribas jr. Enferm Infecc Microbiol Clin (Engl Ed). 2023 Dec;41(10):629-634. doi: 10.1016/j.eimce.2022.12.010. Epub 2023 Jan 7. Enferm Infecc Microbiol Clin (Engl Ed). 2023. PMID: 36624034 Free PMC article. Review.
Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance.
De Miguel Buckley R, Rial-Crestelo D, Montejano R, Pinto A, Jimenez-Gonzalez M, Lagarde M, Esteban-Cantos A, Aranguren-Rivas P, Cadiñanos J, Bisbal O, Castro JM, Santacreu-Guerrero M, Bermejo-Plaza L, Moreno V, Hernando A, Martín-Carbonero L, Rubio R, Delgado R, Arribas JR, Pulido F; Antiretroviral Treatment Guided by Proviral Genotype (ART-PRO) Study Group. De Miguel Buckley R, et al. Among authors: arribas jr. Open Forum Infect Dis. 2022 Nov 8;9(11):ofac610. doi: 10.1093/ofid/ofac610. eCollection 2022 Nov. Open Forum Infect Dis. 2022. PMID: 36447613 Free PMC article.
114 results